Analysis of Graft Failure After Primary Penetrating Keratoplasty in Children With Peters Anomaly.


Journal

Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186

Informations de publication

Date de publication:
Aug 2020
Historique:
pubmed: 7 4 2020
medline: 26 5 2021
entrez: 7 4 2020
Statut: ppublish

Résumé

To investigate the causes of graft failure and risk factors associated with total graft opacity after primary penetrating keratoplasty (PK) in children with Peters anomaly (PA). In this retrospective study, patients with PA (younger than 5 years) who received primary PK in Beijing Tongren Hospital were reviewed. The follow-up period was a minimum of 6 months. A modified PA classification system was used, and all failed grafts were categorized into partial and total opacity groups. Patient demographics, PA classification, operation details, degree of graft opacity, and causes of graft failure were recorded. Of the 165 eyes, 54 eyes (32.7%) demonstrated graft failure along with various degrees of graft opacity. Approximately half of the grafts applied failed within 6 months postoperatively. The partial and total opacity groups did not demonstrate any significant differences regarding diagnosis distribution. Irreversible immune rejection accounted for 61.1% of all graft failures; furthermore, it had a significantly higher proportion in the partial opacity group than in the total opacity group (71.0% and 47.8%, respectively; P = 0.058). The degree of graft opacity was significantly associated with patient age at surgery (P = 0.002), preoperative corneal vascularization (P = 0.009), and iris defects (P = 0.001). However, administration of intensive topical corticosteroids could reduce the risk of total opacity in the rejected grafts. Irreversible immune rejection is the most common cause of graft failure after primary PK in pediatric patients with PA. The degree of graft opacity is closely related to patient age at surgery, preoperative corneal vascularization, and iris defects.

Identifiants

pubmed: 32251169
doi: 10.1097/ICO.0000000000002331
pii: 00003226-202008000-00006
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

961-967

Références

Zaidman GW, Flanagan JK, Furey CC. Long-term visual prognosis in children after corneal transplant surgery for Peters anomaly type I. Am J Ophthalmol. 2007;144:104–108.
Kurilec JM, Zaidman GW. Incidence of Peters anomaly and congenital corneal opacities interfering with vision in the United States. Cornea. 2014;33:848–850.
Nischal KK. A new approach to the classification of neonatal corneal opacities. Curr Opin Ophthalmol. 2012;23:344–354.
Yoshikawa H, Sotozono C, Ikeda Y, et al. Long-Term clinical course in eyes with peters anomaly. Cornea. 2017;36:448–451.
Chang JW, Kim JH, Kim SJ, et al. Long-term clinical course and visual outcome associated with Peters' anomaly. Eye (Lond). 2012;26:1237–1242.
Yang LL, Lambert SR, Lynn MJ, et al. Long-term results of corneal graft survival in infants and children with peters anomaly. Ophthalmology. 1999;106:833–848.
Yang LL, Lambert SR, Drews-Botsch C, et al. Long-term visual outcome of penetrating keratoplasty in infants and children with Peters anomaly. J AAPOS. 2009;13:175–180.
Rao KV, Fernandes M, Gangopadhyay N, et al. Outcome of penetrating keratoplasty for Peters anomaly. Cornea. 2008;27:749–753.
Kim YW, Choi HJ, Kim MK, et al. Clinical outcome of penetrating keratoplasty in patients 5 years or younger: peters anomaly versus sclerocornea. Cornea. 2013;32:1432–1436.
Vanathi M, Panda A, Vengayil S, et al. Pediatric keratoplasty. Surv Ophthalmol. 2009;54:245–271.
Stulting RD, Sumers KD, Cavanagh HD, et al. Penetrating keratoplasty in children. Ophthalmology. 1984;91:1222–1230.
Lin Q, Shi W, Miao S, et al. Visual outcomes and prognostic factors of successful penetrating keratoplasty in 0- to 7-year-old children with congenital corneal opacities. Cornea. 2018;37:1237–1242.
Athanasiadis Y, Tsatsos M, Sharma A, et al. Subconjunctival triamcinolone acetonide in the management of ocular inflammatory disease. J Ocul Pharmacol Ther. 2013;29:516–522.
Athanasiadis I, de Wit D, Tsatsos M, et al. Subconjunctival injection of triamcinolone acetonide in the management of corneal graft rejection and new vessels. J Clin Pharmacol. 2012;52:607–612.
Lowe MT, Keane MC, Coster DJ, et al. The outcome of corneal transplantation in infants, children, and adolescents. Ophthalmology. 2011;118:492–497.
Hovlykke M, Hjortdal J, Ehlers N, et al. Clinical results of 40 years of paediatric keratoplasty in a single university eye clinic. Acta Ophthalmol. 2014;92:370–377.
Srujana D, Kaur M, Urkude J, et al. Long-term functional and anatomic outcomes of repeat graft after optically failed therapeutic keratoplasty. Am J Ophthalmol. 2018;189:166–175.
Vanathi M, Sharma N, Sinha R, et al. Indications and outcome of repeat penetrating keratoplasty in India. BMC Ophthalmol. 2005;5:26.
Medsinge A, Nischal KK. Cataract surgery in children with congenital keratolenticular adhesion (Peters anomaly type 2). J AAPOS. 2015;19:24–28.
Spierer O, Cavuoto KM, Suwannaraj S, et al. Outcome of optical iridectomy in Peters anomaly. Graefes Arch Clin Exp Ophthalmol. 2018;256:1679–1683.
Chan AS, Colby K. Update on pediatric keratoplasty. Int Ophthalmol Clin. 2008;48:25–33.
Michaeli A, Markovich A, Rootman DS. Corneal transplants for the treatment of congenital corneal opacities. J Pediatr Ophthalmol Strabismus. 2005;42:34–44.
Nischal KK. Genetics of congenital corneal opacification—impact on diagnosis and treatment. Cornea 2015;34(suppl 10):S24–S34.
Kusumesh R, Vanathi M. Graft rejection in pediatric penetrating keratoplasty: clinical features and outcomes. Oman J Ophthalmol. 2015;8:33–37.
Morishige N, Sonoda KH. Bullous keratopathy as a progressive disease: evidence from clinical and laboratory imaging studies. Cornea. 2013;32(suppl 1):S77–S83.
Low JR, Anshu A, Tan AC, et al. The outcomes of primary pediatric keratoplasty in Singapore. Am J Ophthalmol. 2014;158:496–502.
Roshandel D, Eslani M, Baradaran-Rafii A, et al. Current and emerging therapies for corneal neovascularization. Ocul Surf. 2018;16:398–414.
Al-Ghamdi A, Al-Rajhi A, Wagoner MD. Primary pediatric keratoplasty: indications, graft survival, and visual outcome. J AAPOS. 2007;11:41–47.
Karadag R, Chan TC, Azari AA, et al. Survival of primary penetrating keratoplasty in children. Am J Ophthalmol. 2016;171:95–100.
Elbaz U, Ali A, Mireskandari K. Long-Term corneal endothelial cell counts after penetrating keratoplasty in infants. Cornea. 2016;35:784–788.
Elbaz U, Mireskandari K, Tehrani N, et al. Corneal endothelial cell density in children: normative data from birth to 5 Years old. Am J Ophthalmol. 2017;173:134–138.
Lagali N, Stenevi U, Claesson M, et al. Survival of donor-derived cells in human corneal transplants. Invest Ophthalmol Vis Sci. 2009;50:2673–2678.
Nischal KK, Lathrop KL. The palisades of vogt in congenital corneal opacification (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2016;114:T8.
Lagali N, Eden U, Utheim TP, et al. In vivo morphology of the limbal palisades of vogt correlates with progressive stem cell deficiency in aniridia-related keratopathy. Invest Ophthalmol Vis Sci. 2013;54:5333–5342.
Bangsgaard R, Main KM, Boberg-Ans G, et al. Adrenal suppression in infants treated with topical ocular glucocorticoids. Ophthalmology. 2018;125:1638–1643.

Auteurs

Yajie Sun (Y)

Beijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Department of Ophthalmology, Henan Provincial People's Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.

Qi Lin (Q)

Department of Ophthalmology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China; and.

Sen Miao (S)

Department of Ophthalmology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Wenying Wang (W)

Beijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Zhiqiang Pan (Z)

Beijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH